Fiscal Year Ending March 2027 Second Quarter (Half-Year) Financial Presentation

Overview of Results

For the first half of the fiscal year ending March 2027, the company recorded a one-time expense in Q2 but remained profitable overall. Revenue was 1,499 million yen, up 500 million yen year-over-year; operating profit (loss) was 0 million yen; and interim net profit (loss) was 4 million yen. The regenerative medicine products business drove revenue increases across segments. Orders for JAC expanded to 210 cases in the first half, totaling 326 cases cumulatively. Contracts for OA reached 158 facilities, while commissioned work from Teijin declined following completion of a know-how provision cycle. Overall, however, the company strengthened its underlying earnings power.

Outlook and Growth Initiatives

While maintaining profitability in the first half, the company will promote order expansion and local deployment across the regenerative medicine products business. Jasmine will accelerate awareness and diffusion of treatments for vitiligo in Japan through a partnership with Maruho Co., Ltd. JAC will collaborate with OSB to promote combined therapies for cartilage repair and osteotomy. The company will expand its lab site business, including establishing a European subsidiary in Germany, and advance local expansion into the European market.